Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

HELLP syndrome blood markers tracked daily in new study

NCT ID NCT06758960

Knowledge-focused Sponsor: CHU Mohammed VI Marrakech Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study observed 72 pregnant women with HELLP syndrome in the ICU. Researchers tracked daily changes in platelets, liver enzymes, and lactate dehydrogenase before and after delivery. The goal was to understand how these biological markers evolve, not to test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

72 people

The number who actually took part.

Started

Jul 2023

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pregnant patients admitted to the maternal ICU from the Obstetrics Emergency department of marrakesh

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pregnant women who are admitted to the maternal ICU for a biological HELLP syndrome Exclusion Criteria: * Patients whose biological presentation was attributable to other conditions, such as microangiopathies or leukemia. * Patients who benefited from plasma exchange therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hellp syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HELLP syndrome Maternal Death preeclampsia thrombocytopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hellp syndrome Preeclampsia

Contacts and locations

Locations

  • CHU Mohammed VI of Marrakech

    Marrakesh, Marrakesh-Safi, 40000, Morocco

More trials for these conditions

Other studies related to the condition(s) this trial covers.